Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presentation of the patient. New biomarkers are available that can assist in the prognosis for patients already diagnosed with heart failure, and can aid in risk stratification, earlier detection of treatment failure, and therapeutic targets.
In this “Hot Topic,” Amy Saenger, Ph.D., DABCC, presents part 2 of a 3-part series on “Laboratory Test Utilization Strategies.” The series addresses strategies for test utilization in the clinical laboratory. This presentation will discuss some common clinical chemistry laboratory tests and strategies to direct appropriate use.
Heart valve infections are one of the complications of implanted cardiac devices. Mayo Clinic’s infectious disease experts are leaders in finding solutions to this problem, and their research has already changed medical practice and helped heart patients everywhere.
Mayo Clinic has developed a novel diagnostic methodology that can subtype amyloidosis in routine biopsy specimens with high accuracy.
One of the feature stories of the August “CAP TODAY”, highlights current and emerging issues related to high-sensitivity troponin assays. Interviewed for the article, “To see troponin’s future, look at the present,” was Allan Jaffe, M.D., Mayo Clinic cardiologist and the division chair of Clinical Core Laboratory Services.
Heart failure mediated by elevated levels of a protein called galectin-3 affects between 30 percent and 50 percent of chronic heart failure patients and is associated with higher rates of mortality and rehospitalization. Mayo Medical Laboratories now offers galectin-3 testing to aid in the prognosis of patients diagnosed with chronic heart failure.